Comparison of BNT162b2 (Biontech/Pfizer) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA Vaccine Immunogenicity in Dialysis Patients

Patients with end-stage renal disease undergoing dialysis are at very high risk of death in case of COVID-191. Growing evidence suggests that a relatively high proportion of dialysis patients develops anti-SARS-Cov2-antibodies after vaccination, albeit to a lesser extent than healthy controls2. Here, we investigated whether there are differences in anti-SARS-CoV2 antibody levels (directed against the receptor binding domain (RBD) of the S1 subunit of the Spike (S) protein, measured with the SARS-CoV-2 IgG II Quant assay, Abbott) in hemodialysis patients without a history of SARS-CoV2-infection after full vaccination (2 doses) with one of the two currently available mRNA-vaccines (BNT162b2, Biontech/Pfizer or mRNA-1273, Moderna) against SARS-CoV2, 3 weeks after administration of the second vaccine dose.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: letters to the editor Source Type: research